Nuvectis Pays $40M Upfront for NXP100, Achieves 59.5% Hemoglobin Normalization
NVCT•In June, Nuvectis Pharma paid $40 million upfront plus up to $1.42 billion in milestones for worldwide rights to NXP100, a once-daily PNH pill that in Phase 3 normalized hemoglobin in 59.5% of patients versus 8.3% on eculizumab. Chinese approvals are expected late 2026 or early 2027, potentially unlocking NXP100’s global launch.
1. Licensing Deal Details
In June 2026, Nuvectis Pharma forged a licensing agreement granting it worldwide rights to NXP100 for $40 million upfront plus up to $1.42 billion in development, regulatory and sales milestones. The deal also includes NXP200, expanding Nuvectis’s oncology pipeline beyond its prior single-drug focus.
2. Phase 3 Clinical Results
NXP100 is a once-daily oral Factor B inhibitor for paroxysmal nocturnal hemoglobinuria (PNH). In a randomized Phase 3 trial, 59.5% of patients on NXP100 achieved normal hemoglobin without transfusion versus 8.3% for the infused standard eculizumab, demonstrating a clear efficacy advantage.
3. Regulatory Timeline and Market Outlook
Two applications for NXP100 are under review in China with decisions anticipated in late 2026 or early 2027. The global PNH treatment market, driven by the shift to oral therapies, is projected to approach $10 billion by 2030, underscoring significant commercial opportunity.
